Illuminating the Path to Better Management: Comprehensive Analysis of Glaucoma Pipeline Featuring 50+ Key Companies | Betaliq, Ocuphire Pharma, HK inno.N, VivaVision Biotech, Qlaris Bio, and others
(Albany, United States) As per DelveInsight’s assessment, globally, the Glaucoma pipeline constitutes 50+ key companies continuously working towards developing 50+ Glaucoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Glaucoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Glaucoma NDA approvals (if any), and product development activities comprising the technology, Glaucoma Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Glaucoma pipeline treatment landscape of the report, click here @ Glaucoma Pipeline Outlook
Key Takeaways from the Glaucoma Pipeline Report
- DelveInsight’s Glaucoma Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
- The leading Glaucoma Companies in the market include Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Ocuphire Pharma, HK inno.N, VivaVision Biotech, Qlaris Bio, and others
- Promising Glaucoma Pipeline Therapies in the various stages of development include rhNGF, Aflibercept (Eylea, BAY 86-5321), Topical IOP-lowering drugs, OPA-6566, Latanoprost, TO-O-1001, ONL1204 Ophthalmic solution (Dose A), and others.
- On March 2023, Theratocular Biotek Co announced a study of phase 1 & 2 clinical trials for TO-O-1001. This study will enroll up to 34 evaluable healthy volunteers in part 1(SAD) and part 2(MD) and 16 evaluable patients with Open-Angle Glaucoma or Ocular Hypertension in part 3(MD).
- On July 2023, ONL Therapeutics announced a study of phase 1 clinical trials for ONL1204 Ophthalmic solution (Dose A) & ONL1204 Ophthalmic solution (Dose B). The purpose of this study is to demonstrate the safety and tolerability of ONL1204 Ophthalmic Solution in patients with progressing open angle glaucoma.
- On June 2023, AbbVie announced a study of phase 1 clinical trials for XEN45 (Glaucoma Gel Stent). All participants will receive XEN45 implanted using the ab externo approach on Day 1 and will be followed for 12 months. Participants will attend regular visits during the study at a hospital or clinic. The safety and effect of the gel stent on your glaucoma will be checked by medical assessments and eye examinations.
Glaucoma Overview
Glaucoma is a group of eye conditions that damage the optic nerve. The optic nerve sends visual information from eye to the brain and is vital for good vision. Damage to the optic nerve is often related to high pressure in your eye.
To explore more information on the latest breakthroughs in the Glaucoma Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight
Glaucoma Emerging Drugs Profile
- GmbH NCX 470: Nicox Ophthalmics
- DE-126: Santen Pharmaceuticals
- POLAT 001: Peregrine Ophthalmic
- BTQ-1902: Betaliq, Inc.
- ST266: Noveome Biotherapeutics
Glaucoma Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Glaucoma Disease. The Glaucoma companies which have their Glaucoma Disease drug candidates in the most advanced stage, i.e. phase III include, Nicox Ophthalmics.
Request a sample and discover the recent advances in Glaucoma Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight
Glaucoma Drugs and Companies
- rhNGF: Dompé Farmaceutici S.p.A
- Aflibercept (Eylea, BAY 86-5321): Bayer
- Topical IOP-lowering drugs: Regeneron Pharmaceuticals
- OPA-6566: Kubota Vision Inc
- Latanoprost: Otsuka Pharmaceuticals Co Ltd
- TO-O-1001: Theratocular Biotek Co
Glaucoma Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Glaucoma Therapeutics Market include-
Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Ocuphire Pharma, HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
Dive deep into rich insights for drugs for Glaucoma Pipeline, click here for Glaucoma Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight
Scope of the Glaucoma Pipeline Report
- Coverage- Global
- Glaucoma Companies- Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Ocuphire Pharma, HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
- Glaucoma Pipeline Therapies- rhNGF, Aflibercept (Eylea, BAY 86-5321), Topical IOP-lowering drugs, OPA-6566, Latanoprost, TO-O-1001, ONL1204 Ophthalmic solution (Dose A), and others.
- Glaucoma Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Glaucoma Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Glaucoma Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Glaucoma Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- NCX 470: Nicox Ophthalmics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- POLAT 001: Peregrine Ophthalmic
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ST266: Noveome Biotherapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- RTC-1119: Ripple Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Glaucoma Disease Key Companies
- Glaucoma Disease Key Products
- Glaucoma Disease- Unmet Needs
- Glaucoma Disease- Market Drivers and Barriers
- Glaucoma Disease- Future Perspectives and Conclusion
- Glaucoma Disease Analyst Views
- Glaucoma Disease Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
